相似文献
1
Targets of new immunosuppressants in renal transplantation.
Kidney Int Suppl (2011). 2011 Aug;1(2):47-51. doi: 10.1038/kisup.2011.12.
2
Novel immunosuppressive agents in kidney transplantation.
Clin Nephrol. 2010 May;73(5):333-43. doi: 10.5414/cnp73333.
3
Potential of emerging immunosuppressive strategies to improve the posttransplant cardiovascular risk profile.
Kidney Int Suppl. 2010 Sep(118):S15-21. doi: 10.1038/ki.2010.211.
4
Sotrastaurin, a protein kinase C inhibitor for the prevention of transplant rejection and treatment of psoriasis.
Curr Opin Investig Drugs. 2009 Nov;10(11):1225-35.
5
Frontiers in immunosuppression.
Transplant Proc. 2011 Apr;43(3):822-5. doi: 10.1016/j.transproceed.2011.02.001.
6
Should belatacept be the centrepiece of renal transplantation?
Nephrol Dial Transplant. 2016 Dec;31(12):1995-2002. doi: 10.1093/ndt/gfw226. Epub 2016 Jun 10.
7
Immunotherapy for De Novo renal transplantation: what's in the pipeline?
Drugs. 2006;66(13):1665-84. doi: 10.2165/00003495-200666130-00002.
8
What's next in the pipeline.
Am J Transplant. 2008 Oct;8(10):1972-81. doi: 10.1111/j.1600-6143.2008.02403.x.
9
Novel immunosuppression: small molecules and biologics.
Semin Nephrol. 2007 Jul;27(4):479-86. doi: 10.1016/j.semnephrol.2007.03.009.
10
A network meta-analysis of the efficacy of belatacept, cyclosporine and tacrolimus for immunosuppression therapy in adult renal transplant recipients.
Curr Med Res Opin. 2014 Aug;30(8):1473-87. doi: 10.1185/03007995.2014.898140. Epub 2014 Apr 3.
本文引用的文献
1
Profile of belatacept and its potential role in prevention of graft rejection following renal transplantation.
Drug Des Devel Ther. 2010 Dec 1;4:375-82. doi: 10.2147/DDDT.S10432.
2
Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients.
Am J Transplant. 2011 Jan;11(1):66-76. doi: 10.1111/j.1600-6143.2010.03338.x. Epub 2010 Nov 29.
3
Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies.
Transplantation. 2010 Dec 27;90(12):1528-35. doi: 10.1097/TP.0b013e3181ff87cd.
4
Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study.
Clin J Am Soc Nephrol. 2011 Feb;6(2):430-9. doi: 10.2215/CJN.05840710. Epub 2010 Nov 4.
5
Five-year safety and efficacy of belatacept in renal transplantation.
J Am Soc Nephrol. 2010 Sep;21(9):1587-96. doi: 10.1681/ASN.2009111109. Epub 2010 Jul 15.
6
Novel immunosuppressive agents in kidney transplantation.
Clin Nephrol. 2010 May;73(5):333-43. doi: 10.5414/cnp73333.
7
A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study).
Am J Transplant. 2010 Mar;10(3):547-57. doi: 10.1111/j.1600-6143.2010.03016.x.
8
A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).
Am J Transplant. 2010 Mar;10(3):535-46. doi: 10.1111/j.1600-6143.2009.03005.x.
9
Sotrastaurin and tacrolimus coadministration: effects on pharmacokinetics and biomarker responses.
J Clin Pharmacol. 2010 Nov;50(11):1260-6. doi: 10.1177/0091270009360534. Epub 2010 Apr 12.
10
Sotrastaurin and everolimus pharmacokinetics after single-dose coadministration.
Int J Clin Pharmacol Ther. 2010 Feb;48(2):103-8. doi: 10.5414/cpp48103.
Zotero 插件